{"id":966023,"date":"2026-05-21T11:56:08","date_gmt":"2026-05-21T15:56:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/"},"modified":"2026-05-21T11:56:08","modified_gmt":"2026-05-21T15:56:08","slug":"tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/","title":{"rendered":"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, May  21, 2026  (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences, Ltd. (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AIFRBUDtW0vcPtoLORr1qcMR4zagNpEDiRKtbBJbApJ-2WVN0ZpYNC4onxn6yJiw6KMh6u7jHhuLQvAsXIorPXLBvGsSZ1GnkE3GvEfmJrS_kOCd6tlrXyNfQpjFgLF-\" rel=\"nofollow\" target=\"_blank\">TLSA<\/a>) (\u201cTiziana\u201d), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10<sup>th<\/sup> joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026.<\/p>\n<p>The trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_xHdM0r9r04njkjM1gB6r51M6UCxM-b-7YZSJaIBYTWJlmJ69E0Y9aDzkpGeo8MhZRYtlTcIppiIBzBaUDccJsTrh63QH66TdXcueEhiTUF7hPZ-mvB9bSujBhgEiYm\" rel=\"nofollow\" target=\"_blank\">NCT06292923<\/a>), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this novel anti-CD3 monoclonal antibody for neurodegenerative and neuroinflammatory diseases. The multicenter study has enrolled 48 patients across multiple leading U.S. sites to receive one of two doses of intranasal foralumab or placebo over a 12-week treatment period, with assessments including PET imaging for microglial activation, MRI, clinical evaluations, and biomarkers. Following the completion of the blinded phase, all participants including those who initially received placebo will have the opportunity to receive intranasal foralumab during a six-month open label extension (OLE) phase. The OLE is designed to assess long term safety and sustained benefit of foralumab in the na-SPMS patient population.<\/p>\n<p>\u201cThis completion of enrollment in our Phase 2a trial represents a pivotal moment for Tiziana Life Sciences and for patients suffering from na-SPMS, a condition with limited treatment options,\u201d said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. \u201cAs the first placebo-controlled trial of intranasal foralumab, this study underscores our commitment to rigorously evaluating this innovative therapy\u2019s potential to modulate the immune system and address neuroinflammation. We are grateful for the dedication of our clinical partners and look forward to sharing topline results that could pave the way for a new treatment paradigm.\u201d<\/p>\n<p>Gabriele Cerrone, Executive Chairman and Founder of Tiziana Life Sciences, added: \u201cReaching full enrollment in this landmark study is a testament to the strong belief in foralumab\u2019s potential and the urgent need for effective therapies in secondary progressive MS. Intranasal delivery offers a novel, non-invasive route that targets the brain\u2019s immune mechanisms directly. This achievement highlights the progress of our pipeline and brings us closer to delivering transformative benefits to patients.\u201d<\/p>\n<p>The Company extends its sincere gratitude to the Principal Investigator, Dr. Tanuja Chitnis, Senior Neurologist at Brigham and Women\u2019s Hospital, a founding member of Mass General Brigham healthcare system along with the entire team of investigators and clinical sites for their exceptional commitment and expertise in advancing this important trial.<\/p>\n<p>For more information on the trial, please visit ClinicalTrials.gov (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_xHdM0r9r04njkjM1gB6h4K0rpxCmUP_V4dbwllOenVz6qj6DkxYV-PoAdN0raXHaOQa6jBOT982m4OwK7y1XE7ri84yXwbofnNBiAmJ1VzO3PlAyzu1utshzDu5nJG\" rel=\"nofollow\" target=\"_blank\">NCT06292923<\/a>).<\/p>\n<p>\n        <strong>About Foralumab<\/strong>\n      <\/p>\n<p>Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_xHdM0r9r04njkjM1gB6r_cxk8VVZmfG6WTalSH9-cORLVXZWbvWENvMr8CD2-WoKvoX8MpvSOPP7Jf51AdndMlN_-py-qQgMltcK4SUQuatJ48HP36rJKgzQXdB33U\" rel=\"nofollow\" target=\"_blank\">NCT06802328<\/a>) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_xHdM0r9r04njkjM1gB6p_ZvnB6h6p0T9h1JnVPek0Uz5ilRV3VglPfHx-WtxWMXk3PVxcjPVi_qLFcWm8a0ZG3aYWVRVPNhjkLYK59zZNRsIqNnEqWVrpDoY6D0Dma\" rel=\"nofollow\" target=\"_blank\">NCT06292923<\/a>).<\/p>\n<p>Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.<sup>[1],[2]<\/sup><sup>,[3]<\/sup><\/p>\n<p>\n        <strong>About Tiziana Life Sciences<\/strong>\n      <\/p>\n<p>Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana\u2019s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.<\/p>\n<p>For more information about Tiziana and its innovative pipeline of therapies, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UXxsT2jhFJfuZWJR5CfMR5faLlKl8LEsdTV_EY7inrPH1PYybuLrAq-eqMHBbqLbqsgBh6l0V93GGxMDWisBE2D-aD4ipG1aEorX3p_l9fmjrHf24Jrw8q4pfLSvs7WM\" rel=\"nofollow\" target=\"_blank\">www.tizianalifesciences.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Tiziana&#8217;s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as &#8216;anticipates,&#8217; &#8216;expects,&#8217; &#8216;intends,&#8217; &#8216;plans,&#8217; &#8216;believes,&#8217; &#8216;seeks,&#8217; &#8216;estimates,&#8217; and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Tiziana&#8217;s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled \u2018Risk Factors\u2019 in Tiziana\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.<\/p>\n<p>\n        <strong>For further inquiries:<\/strong>\n      <\/p>\n<p>\n        <strong>Tiziana Life Sciences Ltd<\/strong><br \/>\n        <br \/>Paul Spencer, Business Development, and Investor Relations<br \/>+44 (0) 207 495 2379<br \/>email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LRNyhKkJ-nHWQylk0RxZ9nNyG8s15xYjhsFfJKciE95u0i29gYKEAR4HaiSM3qXpciHnra3jWMPgR_tU6IirVkBrBw_8YuDcig1a1tg9nHzpbnxXXz0MSHcwhSNga9p8\" rel=\"nofollow\" target=\"_blank\">info@tizianalifesciences.com<\/a><\/p>\n<p>[1] <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WN4xeNFIoJZGL1RjHW2dScyL-e9kxXnyiNxasWMIntx2_-vpxkWa7zl1xaqo2Cj2hbvPxqs5jXTmqpzql3eSg5JkzWdc5B6gx7woV6pHUNhbTB8lg4DLu_JPE9mMXDfv0EFWx4pZmE_HZdPRm94WfoAicDuoTL1nIurNw-xrH2E=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2220272120<\/a><br \/>[2]\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WN4xeNFIoJZGL1RjHW2dScyL-e9kxXnyiNxasWMIntx2_-vpxkWa7zl1xaqo2Cj21zczlZUG2GoBezq9JJbegsxVRKwmqH9Au3o_kgDdC3jHBYwplD5IdF9SofjNUziUL2ZEFScezivVPeYyDHdFg6EXNpeMuPID7NYWIZZkLxY=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2309221120<\/a><br \/>[3] <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WN4xeNFIoJZGL1RjHW2dSRddzVKvwNL4FknM18mtMB_qNVdag7tVepr3rtUg81-r1jd9LfTMWq7jGxEQ5AZ3nBoh97gkPjawVuqbK2NOe6mf51uqWLTQztbZ-mJx64gjGNBUGQ34FMLHKmSQnAE53VW61bg2XkpRq1KCRoUtcKG9bWAza-McDjR5XUJ5LuqLc3ZWgb3IOIXQ3EgXszlp4w==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200543<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWJlMzAzN2UtODY1Ni00NTBhLWE4ZTgtNjE3MThjNmNjYjFlLTExMzU0NTYtMjAyNi0wNS0yMS1lbg==\/tiny\/Tiziana-Life-Sciences-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences, Ltd. (Nasdaq:\u00a0TLSA) (\u201cTiziana\u201d), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026. The trial (NCT06292923), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966023","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, May 21, 2026 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences, Ltd. (Nasdaq:\u00a0TLSA) (\u201cTiziana\u201d), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026. The trial (NCT06292923), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this &hellip; Continue reading &quot;Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T15:56:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial\",\"datePublished\":\"2026-05-21T15:56:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/\"},\"wordCount\":1001,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/\",\"name\":\"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=\",\"datePublished\":\"2026-05-21T15:56:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - Market Newsdesk","og_description":"BOSTON, May 21, 2026 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences, Ltd. (Nasdaq:\u00a0TLSA) (\u201cTiziana\u201d), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026. The trial (NCT06292923), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this &hellip; Continue reading \"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T15:56:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial","datePublished":"2026-05-21T15:56:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/"},"wordCount":1001,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/","name":"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=","datePublished":"2026-05-21T15:56:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDcwMiM3NjE1NzY1IzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966023"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966023\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}